Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125883 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Aleksandra Bołdys und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752…. Hauptthemen laut MEDLINE: Liraglutide, Obesity, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia, Medical University of Silesia in Katowice.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of liver cirrhosis, with its global prevalence rising due to obesity, insulin resistance, and type 2 diabetes mellitus. While bariatric surgery remains effective for weight loss, Glucagon-Like Peptide-1 analogs such as liraglutide are emerging as promising pharmacological treatments. This study aimed to evaluate the effects of a 3-month liraglutide treatment on liver steatosis, subclinical markers, and insulin resistance in non-diabetic, obese patients with MASLD. Twenty-eight obese adults (BMI ≥ 30 kg/m2) were treated with daily subcutaneous liraglutide injections for three months. Liver steatosis was assessed using FibroScan® (CAP score) and non-invasive indices (Hepatic Steatosis Index—HSI, and NAFLD Liver Fat Score—NLFS). Insulin resistance was measured with conventional markers (HOMA-IR, QUICKI) and triglyceride-based indices (METS-IR, TyG). Liraglutide significantly reduced liver steatosis (CAP score: 305 to 268 dB/m, p < 0.05) and improved HSI, while NLFS remained unchanged. Despite significant weight loss, traditional insulin resistance markers remained unchanged, while METS-IR and TyG improved. Liraglutide therapy improved liver steatosis and triglyceride-based insulin resistance markers in non-diabetic obese patients with MASLD. These findings support the use of liraglutide, highlighting the value of personalized approaches and alternative insulin resistance assessments in MASLD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.
ORCID-Profile: Aleksandra Bołdys, Łukasz Bułdak, Bogusław Okopień
Förderung
- Medical University of Silesia
- Medical University of Silesia in Katowice
Zitieren
APA
Bołdys, A., Bułdak, Ł., Nicze, M., & Okopień, B. (2025). Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125883
Vancouver
Bołdys A, Bułdak Ł, Nicze M, Okopień B. Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125883
BibTeX
@article{Bodys2025,
author = {Bołdys, Aleksandra and Bułdak, Łukasz and Nicze, Michał and Okopień, Bogusław},
title = {Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125883}
}
EUVIMED